1Hirsh J,Fuster V.Guide to anticoagulant therapy.Part 2:Oral anticoagulants.American Heart Association.Circulation,1994,89:1469-1480.
2Fasco MJ,Hildebrandt EF,Suttie JW.Evidence that warfarin anticoagulant action involves two distinct reductase activities.J Biol Chem,1982,257:11210-11212.
3Higashi M,Veenstra DL,Wittkowsky AK,et al.Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.JAMA 2002,287:1690-1698.
4Banet GA,Waterman AD,Milligan PE,et al.Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio.Chest,2003,123:499-503.
5Algra A.European-Australian Stroke Prevention in Reversible.Warfarin or aspirin for recurrent ischemic stroke.N Engl J Med,2002,346:1169-1171.
6Preston FE,Laidlaw ST,Sampson B,et al.Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex):efficacy and safety in patients.Br J Haematol,2002,116:619-624.
8Hirsh J,Fuster V,Ansell J,et al.American Heart Association/American Co-llege of Cardiology Foundation guide to warfarin therapy.J Am Coll Cardiol,2003,41:1633-1652.
同被引文献2
1Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in Patients with acute coronary syndromes without ST-segment elevation[J].N Engl J Med,2001,345(7):494-502.
2De Luca G,Suryapranata H,Stone GW,et al.Abciximab as adjunctive therapy to reperfusion in acute ST-segment ele-vation myocardial infarction:a meta-analysis of randomized trials[J].JAMA,2005,293(14):1759-1765.
